Bone Biologics Corp Exhibit
EX-99.1 2 ex99-1.htm   EXHIBIT 99.1   Bone Biologics : Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation   01/07/2020 | 02:09pm EST   Bone Biologics (OTCQB: BBLG),…
To view the full exhibit click here

Story continues below


Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX.

An ad to help with our costs